To the Editor We read with interest the recent article by Jackson et al¹ in JAMA Oncology on aspirin (acetylsalicylic acid) therapy in patients with biliary tract cancer (BTC). The authors conducted a retrospective cohort study using data from the UK’s Clinical Practice Research Datalink (CPRD) to test the hypothesis that aspirin’s anti-inflammatory mechanism may slow the spread of BTC. Analysis of overall survival was stratified by aspirin prescription and BTC subtype. The results are impressive, with adjusted mortality hazard ratios ranging from 0.44 to 0.71, all statistically significant. Kaplan-Meier survival estimates showed that median overall survival was barely reached in the aspirin cohort. These results were interpreted to show that the survival benefit of aspirin is on par with the current standard therapy for BTC.¹ We commend the authors on this innovative, thought-provoking research.

致编辑我们感兴趣地阅读了Jackson等人¹在JAMA肿瘤学杂志上的最新文章阿司匹林（乙酰水杨酸）治疗胆道癌（BTC）的患者 作者使用来自英国临床实践研究数据链（CPRD）的数据进行了一项回顾性队列研究，以检验阿司匹林的抗炎机制可能减慢BTC扩散的假说。通过阿司匹林处方和BTC亚型对总生存期进行分层。结果令人印象深刻，调整后的死亡危险比从0.44到0.71，均具有统计学意义。Kaplan-Meier生存估计表明，阿司匹林组几乎没有达到中位总体生存。这些结果被解释为表明阿司匹林的生存益处与当前的BTC标准疗法相当。¹我们赞扬作者的这项创新，发人深省的研究。